Neutralisation of Soluble Tumor Necrosis Factor

Frontiers of Gastrointestinal Research

Volumn 34, Issue , 2015, Pages 83-89

  Dreesen, Erwin ^a   Gils, Ann ^a,b  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b Pharmaceutical and Pharmacological Sciences Department Leuven KU   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BINDING AFFINITY; BODY WEIGHT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; PATHOPHYSIOLOGY; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REMISSION; VOLUME OF DISTRIBUTION;

EID: 84937943980     PISSN: 03020665     EISSN: 16623754     Source Type: Book Series    
DOI: 10.1159/000381446     Document Type: Article

References (44)

1. Vermeire S, Van Assche G, Rutgeerts P: Classification of inflammatory bowel disease: the old and the new. Curr Opin Gastroenterol 2012; 28: 321-326.
2. Basso PJ, Fonseca MT, Bonfá G, Alves VB, Sales-Campos H, Nardini V, Cardoso CR: Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease. Braz J Med Biol Res 2014; 47: 727-737.
3. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117: 244-279.
4. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 913-917.
5. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT: Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
6. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT: Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-1709.
7. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, Tsuji N, Sakamaki S, Niitsu Y, Watanabe N: Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297-1301.
8. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT: Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-1466.
9. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT: Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993; 46: 757-760.
10. Apostolaki M, Armaka M, Victoratos P, Kollias G: Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr Dir Autoimmun 2010; 11: 1-26.
11. Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S: Targeting TNF-? for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014; 14: 75-101.
12. Kriegler M, Perez C, DeFay K, Albert I, Lu SD: A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
13. Wolfsberg TG, White JM: ADAMs in fertilization and development. Dev Biol 1996; 180: 389-401.
14. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
15. Smith RA, Baglioni C: The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262: 6951-6954.
16. Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P: The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793-802.
17. Grell M, Wajant H, Zimmermann G, Scheurich P: The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 1998; 95: 570-575.
18. Tartaglia LA, Pennica D, Goeddel DV: Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268: 18542-18548.
19. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV: A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845-853.
20. Hsu H, Xiong J, Goeddel DV: The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81: 495-504.
21. Baud V, Karin M: Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 2001; 11: 372-377.
22. Medvedev AE, Espevik T, Ranges G, Sundan A: Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem 1996; 271: 9778-9784.
23. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453.
24. Mouser JF, Hyams JS: Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn's disease. Clin Ther 1999; 21: 932-942.
25. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR: Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) 1994; 12: 899-903.
26. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349: 521-524.
27. Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G, Tam S, Sague S, Wang D, Brigham-Burke M, Dalmonte P, Emmell E, Pikounis B, Bugelski PJ, Zhou H, Scallon BJ, Giles-Komar JM: Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor ?. MAbs 2010; 2: 428-439.
28. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Hibi T, Rutgeerts P, PURSUIT-SC Study Group: Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95.
29. Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W, Gibson PR, Collins J, Järnerot G, Rutgeerts P, Group P-MS: Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 96-109.
30. Goel N, Stephens S: Certolizumab pegol. MAbs 2010; 2: 137-147.
31. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094.
32. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K: Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001; 299: 119-129.
33. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426.
34. Klotz U, Teml A, Schwab M: Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007; 46: 645-660.
35. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK: Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factoralpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-1721.
36. Lobo ED, Hansen RJ, Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-2668.
37. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H: Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-1228.
38. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM: Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011; 33: 946-964.
39. Brambell FW, Hemmings WA, Morris IG: A theoretical model of gamma-globulin catabolism. Nature 1964; 203: 1352-1354.
40. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS: Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010; 30: 777-789.
41. Wang W, Wang EQ, Balthasar JP: Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
42. Löwenberg M, D'Haens G: Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep 2013; 15: 311.
43. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L, Van Huysse J, Demetter P, Steidler L, Remaut E, Cuvelier C, Rottiers P: Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010; 3: 49-56.
44. Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N: Orally delivered thioketal nanoparticles loaded with TNF-?-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010; 9: 923-928.